Abstract

AIDS: The newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (Sustiva), was added to the Department of Health and Human Services' (DHHS) "Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents" as a preferred component of combination anti-HIV therapy, in 1998. Efavirenz is the first non-protease inhibitor drug to be included as a preferred agent. The other NNRTIs, nevirapine and delavirdine, are included as "alternative" recommendations. More information was added to the guidelines, including adverse effects of anti-HIV drugs and drug resistance testing. A web address for the full guidelines is provided.